MaxCyte Inc Aktie News

MaxCyte, Inc. ( MXCT ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Maher Masoud - President, CEO & Executive Director Douglas Swirsky - Chief Financial Officer Conference Call Participants Matthew Larew - William Blair & Company L.L.C., Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Vidyun Bais - BTIG, LLC, Research Division Han...

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Chief Financial Officer Douglas Swirsky has informed the Company of his decision to transition from his role in...

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its third quarter ended September 30, 2025 financial results and reiterated its 2025 guidance.

MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November 19, 2025 ROCKVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discove...

ROCKVILLE, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the third quarter 2025 after the U.S. market close on Wednesday, November ...

MaxCyte's Flow Electroporation® Technology will support efficient gene delivery to advance Moonlight Bio's engineered T cell therapies MaxCyte's Flow Electroporation® Technology will support efficient gene delivery to advance Moonlight Bio's engineered T cell therapies

ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced a restructuring of its operations to better align resources with its strategic priorities. This plan includes a red...

MaxCyte, Inc. (NASDAQ:MXCT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Douglas J. Swirsky - Chief Financial Officer Maher Masoud - President, CEO & Executive Director Conference Call Participants Brendan Mychal Smith - TD Cowen, Research Division Hannah Webb Hefley - Stephens Inc., Research Division Matthew Richard Larew - William Blair & Company L.L.C.